Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation

The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation protocols in women undergoing in vitro fertilisation.

Inclusion Criteria:

• Women aged 18-36 years old with a body weight of more than 60 kg up to 90 kg
• BMI of 18-32 kg/m2
• Menstrual cycle length of 23-35 days
• An indication for controlled ovarian stimulation for IVF or ICSI

Exclusion Criteria:

• history of an endocrine abnormality
• abnormal outcome of blood biochemistry or hematology
• abnormal cervical smear
• chronic disease
• uterine pathology that interfering with the COS treatment (e.g. fibroids ≥ 5 cm)